Physician profile
Michael Thomas Slaughter
NPI 1306815394
$17,371.30
in general payments reported to CMS, 2019-2025
72 companies · $3,094 in 2025
The $3,094 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,872 · 2020: $1,452 · 2021: $2,466 · 2022: $3,483 · 2023: $1,496 · 2024: $2,509 · 2025: $3,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,714 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,714.46 |
| Education | $384.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,638.12 | 2019-2025 | |
| Amgen INC. | $1,151.90 | 2019-2025 | Imdelltra (Amg757), Vectibix, Nplate |
| Merck Sharp & Dohme LLC | $1,108.14 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,038.44 | 2019-2025 | Imbruvica, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $981.10 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $813.98 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Pfizer INC. | $805.43 | 2019-2025 | |
| Eisai INC. | $746.61 | 2019-2025 | |
| Seagen INC. | $618.57 | 2019-2022 | |
| Celgene Corporation | $593.28 | 2019-2025 | Reblozyl |
| Exelixis INC. | $583.22 | 2019-2025 | Cabometyx |
| Incyte Corporation | $529.79 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $512.83 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Abbvie INC. | $509.85 | 2020-2025 | Venclexta |
| Genzyme Corporation | $506.28 | 2019-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Slaughter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.